BIOTECHNOLOGY UPDATE

whitePaper | December 6, 2022

The development of Advanced Therapy Medicinal Products such as gene and cell therapy products, has made significant progress in the treatment of many diseases, including cancer, genetic, and autoimmune disorders.

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.